AbCellera reports Q3 2026 results and breakthrough Phase 2 data for ABCL635
AbCellera Biologics announced its third‑quarter 2026 financial results, posting revenue of $10.6 million and a net loss of $40.8 million, or $(0.13) per share, compared with a $57.1 million loss a year earlier. The company also disclosed positive top‑line Phase 2 data for its lead program ABCL635, showing an 83% reduction in vasomotor symptom frequency and a 58% reduction in severity versus placebo. Management said the data support moving ABCL635 into late‑stage development in 2027 and expanding its indication set.
Why it matters
The narrowed loss and $200 million capital raise increase available liquidity to over $890 million, giving the company runway to fund late‑stage trials (the company expects to start them in 2027). The strong Phase 2 results could create a new revenue stream if the program reaches market, which may improve future earnings outlook.
Key facts
- 1Total revenue was $10.6 million, up from $9.0 million in Q3 2025. sec.gov
- 2Net loss was $40.8 million, or $(0.13) per share, versus $57.1 million a year earlier. sec.gov
- 3The company completed a $200 million offering, raising total available liquidity to approximately $900 million. sec.gov
- 4Phase 2 trial of ABCL635 showed an 83% reduction in vasomotor symptom frequency and a 58% reduction in severity versus placebo. investing.com
- 5ABCL635 is planned to enter late‑stage development in 2027 and to be evaluated for additional indications such as cancer‑treatment‑related hot flashes. finance.yahoo.com
- 6Cash and marketable securities total $790 million, with total available liquidity exceeding $890 million. sec.gov
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.